Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The US Food and Drug Administration (FDA) has recently licensed a form of ketamine – esketamine – as a treatment for depression which is resistant to other treatments. It is administered as a nasal spray in a clinic, initially twice a week, then weekly or fortnightly. Regular doses of the drug are necessary to prevent relapse.

image shows hand holding a nasal spray which administers the drug.

In the US, patients who start esketamine ($600 a dose) are asked about whether they have previously taken ketamine ($10 a dose), but not the other way round.

Associate Professor Rupert McShane, University of Oxford, says,

"History teaches us just how important it is to track patients who switch from one potentially addictive drug to another. European and UK regulators urgently need to ensure that treatments with ketamine, and other potentially addictive drugs, are all tracked in the same system along with esketamine. This same logic applies to people who are self-treating without a prescription. This sensible precaution would help prevent esketamine from suffering the same fate as benzodiazepines: overuse, backlash and stigma."

 

Patients' experiences matter – this sort of data platform will give them a voice.Associate Professor Rupert McShane.

 

Read the full article authored by Rupert McShane and Adam Winstock.

NIHR OXFORD HEALTH BIOMEDICAL RESEARCH CENTRE NEWS

Please follow the link below to read the news on the NIHR BRC website.

Similar stories

New Study Shows Simvastatin Can Change the Way People Experience Certain Emotions

This new study examines the effects of simvastatin on emotional processing, reward learning, verbal memory, and inflammation.

Oxford researchers part of major UK initiative to understand chronic pain

Oxford pain researchers are playing a major role in a new multi-million pound research programme launched by a consortium of funders, including UKRI, Versus Arthritis, Eli Lilly and the Medical Research Foundation.

Anxiety Disorders Among Children, Assessment and Working with Families

Anxiety disorders are the most common mental health disorders among children, yet there is limited guidance on the process of assessing child anxiety disorders and sharing diagnostic outcomes with families.

Landmark New Clinical Trial Shows Benefits of Automated Virtual Reality (VR) Treatment for Severe Psychological Problems

The gameChange automated VR program is designed to treat agoraphobia in patients with psychosis. In the largest ever clinical trial of virtual reality for mental health, gameChange especially helped people whose anxiety had previously left them virtually housebound.

UK-Japanese Collaboration Researches Mental Health Challenges Faced by Young People and their Families

Dr Simona Skripkauskaite, Departments of Psychiatry and Experimental Psychology, University of Oxford, is the UK lead for one of the ten collaborative research projects jointly awarded by the Economic and Social Research Council (ESRC), the Arts and Humanities Research Council (AHRC) and the Japan Society for the Promotion of Science (JSPS), to address the challenges presented by the global pandemic.

Department of Psychiatry Recognition Awards

Today we announce the prize winners of the first Department of Psychiatry Recognition Awards. One award is designed to offer early career researchers (ECRs) the opportunity to showcase their work, motivations and aspirations for research into mental health. Alongside this we launch the 'Good Citizen' award, where all department members have been able to make nominations.